製品番号: HY-N1996

Chebulagic acid

5 Cited Publications

カスタマーレビュー

Based on 5 publication(s) in Google Scholar

Chebulagic acid is a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz, on angiogenesis. Chebulagic acid is a M2 serine to asparagine 31 mutation (S31N) inhibitor and influenza antiviral. Chebulagic acid also against SARS-CoV-2 viral replication with an EC₅₀ of 9.76 μM.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.66%
CAS 番号: 23094-71-5
分子式: C₄₁H₃₀O₂₇
分子量:954.66

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Chebulagic acid 構造式

CAS 番号: 23094-71-5

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

COX アイソフォーム固有の製品をすべて表示 :

Lipoxygenase アイソフォーム固有の製品をすべて表示 :

体外実験

Chebulagic acid can enhance the autophagy. Chebulagic acid exert anti-inflammatory and anti-infective effects. Chebulagic acid also shows a protective effect against 1-methyl-4-phenylpyridinium (MPP+)-induce cytotoxicity which mimics the pathological symptom of Parkinson's disease. Chebulagic acid inhibits the LPS-induced upregulation of TNF-α and IL-1β in a dose- and time-dependent manner. Furthermore, LPS-activated MAPK signaling is inhibited by Chebulagic acid treatment in the EA.hy926 cells.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 23094-71-5
性状 Solid
分子量 954.66
分子式 C₄₁H₃₀O₂₇
Color White to light yellow
SMILES

OC(CC(C(O[C@H]([C@@H](COC(C1=CC(O)=C2O)=O)O[C@@H]3OC(C4=CC(O)=C(O)C(O)=C4)=O)[C@H](OC(C5=CC(O)=C(O)C(O)=C5C1=C2O)=O)[C@H]3OC6=O)=O)C(C7O)C(C6=CC(O)=C8O)=C8OC7=O)=O
Structure Classification
- Phenols
- Polyphenols
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All ELISART-PCRWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cell Commun Signal

Nesfatin-1 enhances vascular smooth muscle calcification through facilitating BMP-2 osteogenic signaling. [Abstract]

2024 Oct 11;22(1):488. PMID: 39394127
Pharmaceutics

Inhibition of SARS-CoV-2-Induced NLRP3 Inflammasome-Mediated Lung Cell Inflammation by Triphala-Loaded Nanoparticle Targeting Spike Glycoprotein S1. [Abstract]

2024 Jun 2;16(6):751. PMID: 38931873

Chebulagic acid purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2024 Jun 2;16(6):751. [Abstract]

A549 cells were pre-treated with active compounds (Gallic acid, Chebulagic acid, and Chebulinic acid) (0–20 µg/mL) for 24 h. Then, the cells were exposed to CoV2-SP (100 ng/mL) for 3 h. The IL-6 (A), IL-1β (B), and IL-18 secretions (C) in the culture supernatant were examined by ELISA.

Chebulagic acid purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2024 Jun 2;16(6):751. [Abstract]

Inhibitory effects of active compounds (Gallic acid, Chebulagic acid and Chebulinic acid) on the IL-6 (A), IL-1β (B), IL-18 (C), and NLRP3 gene expressions (D) in CoV2-SP-induced A549 cells. A549 cells were pre-treated with active compounds (gallic acid, chebulagic acid and chebulinic acid) (0–20 µg/mL) for 24 h. Then, the cells were exposed to CoV2-SP (100 ng/mL) for 3 h. The mRNA expressions were determined using RT-qPCR.

Chebulagic acid purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2024 Jun 2;16(6):751. [Abstract]

The effects of Chebulagic acid and chebulinic acid inhibited the NLRP3 inflammasome pathway in CoV2-SP-induced A549 cells. A549 cells were pre-treated with chebulagic acid and Chebulinic acid (0–20 µg/mL) for 24 h. Then, the cells were exposed to CoV2-SP (100 ng/mL) for 3 h. The inhibitory effects of chebulagic acid and chebulinic acid on the expression of NLRP3, ASC, and pro-caspase-1 (p50) and cleaved-caspase-1 (p20) proteins in A549 cells are displayed in western blot.

Chebulagic acid purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2024 Jun 2;16(6):751. [Abstract]

Chebulagic acid (0-50 μg/mL; 24, 48 h) showed no cytotoxicity towards A549 cells.
Molecules

Virtual Screening Identifies Chebulagic Acid as an Inhibitor of the M2(S31N) Viral Ion Channel and Influenza A Virus. [Abstract]

2020 Jun 24;25(12):2903. PMID: 32599753
Antiviral Res

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro. [Abstract]

2021 Jun:190:105075. PMID: 33872675

Chebulagic acid purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2021 Jun:190:105075. [Abstract]

Chebulagic acid (CHLA; 3.7, 11.1, 33.3 μM; 48 h) inhibited the plaque formation of SARS-CoV-2 in a dose-dependent manner (Vero-E6 monolayers grown in 12-well plates were pre-treated with increasing concentrations of test compound for 1 h, followed by infection with SARS-CoV-2 (MOI of 0.0001) in the presence of test compounds).
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (104.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.0475 mL

5.2375 mL

10.4749 mL

5 mM

0.2095 mL

1.0475 mL

2.0950 mL

10 mM

0.1047 mL

0.5237 mL

1.0475 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.83 mg/mL (0.87 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.83 mg/mL (0.87 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.83 mg/mL (0.87 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (284 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Kim HJ et al. Neuroprotective Effect of Chebulagic Acid via Autophagy Induction in SH-SY5Y Cells. Biomol Ther (Seoul). 2014 Jul;22(4):275-81. [Content Brief]

[2]. Liu Y et al. Chebulagic acid inhibits the LPS-induced expression of TNF-α and IL-1β in endothelial cells by suppressing MAPK activation. Exp Ther Med. 2015 Jul;10(1):263-268. [Content Brief]

[3]. Athira AP et al. Inhibition of Angiogenesis In Vitro by Chebulagic Acid: A COX-LOX Dual Inhibitor. Int J Vasc Med. 2013;2013:843897. [Content Brief]

[4]. Maggie C. Duncan, et al. Virtual Screening Identifies Chebulagic Acid as an Inhibitor of the M2(S31N) Viral Ion Channel and Influenza A Virus. Molecules 2020, 25, 2903.

[5]. RuikunDu, et al. Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CLpro. Antivir Res. 2021, 105075.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.0475 mL	5.2375 mL	10.4749 mL	26.1873 mL
	5 mM	0.2095 mL	1.0475 mL	2.0950 mL	5.2375 mL
	10 mM	0.1047 mL	0.5237 mL	1.0475 mL	2.6187 mL
	15 mM	0.0698 mL	0.3492 mL	0.6983 mL	1.7458 mL
	20 mM	0.0524 mL	0.2619 mL	0.5237 mL	1.3094 mL
	25 mM	0.0419 mL	0.2095 mL	0.4190 mL	1.0475 mL
	30 mM	0.0349 mL	0.1746 mL	0.3492 mL	0.8729 mL
	40 mM	0.0262 mL	0.1309 mL	0.2619 mL	0.6547 mL
	50 mM	0.0209 mL	0.1047 mL	0.2095 mL	0.5237 mL
	60 mM	0.0175 mL	0.0873 mL	0.1746 mL	0.4365 mL
	80 mM	0.0131 mL	0.0655 mL	0.1309 mL	0.3273 mL
	100 mM	0.0105 mL	0.0524 mL	0.1047 mL	0.2619 mL

Keywords

Chebulagic acid

5 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Chebulagic acid

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Metabolic Enzyme Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Chebulagic acid

COX アイソフォーム固有の製品をすべて表示

Lipoxygenase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (5)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Chebulagic acid 関連分類

製品番号: HY-N1996